openPR Logo
Press release

Alzheimer's Disease Diagnostic Market to Reach $8.07 Billion by 2030, Growing at 12.8% CAGR

Alzheimer's Disease Diagnostic Market

Alzheimer's Disease Diagnostic Market

Alzheimer's Disease Diagnostic Market Poised for Significant Growth

Projected to Reach USD 8.07 Billion by 2030 at a CAGR of 12.8%

The global Alzheimer's disease diagnostic market is experiencing robust growth, with market size expected to escalate from USD 3.47 billion in 2023 to approximately USD 8.07 billion by 2030, reflecting a compound annual growth rate (CAGR) of 12.8%.

Curious to peek inside? Grab your sample copy of this report now:https://www.maximizemarketresearch.com/request-sample/116921/

Market Dynamics and Growth Drivers

The surge in Alzheimer's disease prevalence, coupled with advancements in diagnostic technologies and an increasing emphasis on early detection, are pivotal factors propelling market expansion. Innovations such as biomarker-based diagnostics and neuroimaging techniques have significantly enhanced the accuracy and timeliness of Alzheimer's diagnosis, thereby improving patient outcomes.

Competitive Landscape

The Alzheimer's disease diagnostic market is characterized by the presence of several key players driving innovation and development:

Eli Lilly and Company: Investing heavily in blood tests and biomarker research for early-stage Alzheimer's detection.

Hoffmann-La Roche: Pioneering advancements in biomarker testing and imaging techniques.

Novartis AG: Focusing on developing comprehensive diagnostic solutions.

Merck & Co.: Engaged in extensive research to enhance diagnostic accuracy.

Pfizer Inc.: Contributing to the development of innovative diagnostic tools.

Allergan PLC: Expanding its portfolio in neurological diagnostics.

Daiichi Sankyo Co.: Advancing diagnostic methodologies for better patient care.

Eager to discover what's within? Secure your sample copy of the report today:https://www.maximizemarketresearch.com/request-sample/116921/

Regional Insights

United States: Growth and Consolidation

The United States remains a dominant force in the Alzheimer's diagnostics market, attributed to its advanced healthcare infrastructure and substantial investment in research and development. A notable development is AbbVie's agreement to acquire Aliada Therapeutics for $1.4 billion, aiming to bolster its neuroscience pipeline with innovative Alzheimer's therapies.

Asia Pacific: Opportunities and Trends

The Asia Pacific region is witnessing a surge in demand for Alzheimer's diagnostics, driven by aging populations and increased healthcare awareness. Countries like Japan and South Korea are at the forefront, integrating advanced imaging techniques alongside biomarker testing to improve diagnostic accuracy.

Europe: Trends and Updation

Europe is actively enhancing its Alzheimer's diagnostic capabilities through significant investments in research and development. The European Union is funding projects focused on developing non-invasive diagnostic tools and integrating digital health solutions, reflecting a commitment to early detection and improved patient care.

Middle East and Africa: Emerging Opportunities

The Middle East and Africa are gradually recognizing the importance of early Alzheimer's diagnosis. Efforts are underway to improve healthcare infrastructure and increase awareness, aiming to meet the growing demand for diagnostic services in these regions.

Intrigued to explore the contents? Secure your hands-on sample copy of the report:https://www.maximizemarketresearch.com/request-sample/116921/

Market Segmentation: In-Depth Analysis:

by Specimen

Cholinesterase Inhibitors
NMDA Receptor Antagonist
Other

Over the course of the projected period, cholinesterase inhibitors are anticipated to increase their market share the most. Prominent pharmacological activities, such as preventing the loss of mental function in dementia and Alzheimer's disease patients, are the main reasons driving the market's rise. Additionally, the level of cholinesterase can serve as a proxy for exposure to arsenic. The symptoms of memory, thinking, language, judgment, and other stimulating processes or reactions are treated with cholinesterase inhibitors.

by Diagnostics

Brain Imaging
CFS Test for Alzheimer's Diseases

The global market for Alzheimer's disease diagnostics is dominated by the CFS Test for Alzheimer's Diseases. The growing usage of cerebrospinal fluid (CSF) in Alzheimer's disease diagnosis is one of the main factors driving the market's expansion. An injection is used to remove the sample CSF from the patient's back. Thanks to digital scanning, braine imaging is becoming more widely accepted in the market and has been essential in the study and diagnosis of Alzheimer's disease (AD). In order to rule out the etiology of dementia, diagnostic brain imaging techniques such as computed tomography (CT) and magnetic resonance imaging (MRI) are employed.

For deeper market insights, peruse the summary of the research report:https://www.maximizemarketresearch.com/market-report/global-alzheimers-disease-diagnostic-market/116921/

Learn about the top players driving innovation in the Market :

1. Eli Lilly and Company
2. TauRx (Republic of Singapore)
3. Alector LLC
4. Accera, Inc.
5. Treventis Corporation
6. Neuro-Bio Ltd
7. Cognition Therapeutics Inc
8. Hoffmann-La Roche
9. Novartis AG
10. Merck & Co.
11. Pfizer Inc.
12. Allergan PLC
13. Daiichi Sankyo Co.

Get Market Research Latest Trends :

Bulimia Nervosa Market https://www.maximizemarketresearch.com/market-report/bulimia-nervosa-market/188570/

Bone Screw System Market https://www.maximizemarketresearch.com/market-report/bone-screw-system-market/121454/

Mother Child Healthcare Market https://www.maximizemarketresearch.com/market-report/mother-child-healthcare-market/187324/

Global Bioengineered Protein Drugs Market https://www.maximizemarketresearch.com/market-report/global-bioengineered-protein-drugs-market/39151/

Pregabalin Market https://www.maximizemarketresearch.com/market-report/global-pregabalin-market/109027/

Contact Maximize Market Research:

3rd Floor, Navale IT Park, Phase 2
Pune Banglore Highway, Narhe,
Pune, Maharashtra 411041, India
sales@maximizemarketresearch.com
+91 96071 95908, +91 9607365656

About Maximize Market Research:

Maximize Market Research is a multifaceted market research and consulting company with professionals from several industries. Some of the industries we cover include medical devices, pharmaceutical manufacturers, science and engineering, electronic components, industrial equipment, technology and communication, cars and automobiles, chemical products and substances, general merchandise, beverages, personal care, and automated systems. To mention a few, we provide market-verified industry estimations, technical trend analysis, crucial market research, strategic advice, competition analysis, production and demand analysis, and client impact studies.

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Alzheimer's Disease Diagnostic Market to Reach $8.07 Billion by 2030, Growing at 12.8% CAGR here

News-ID: 3921737 • Views:

More Releases from MAXIMIZE MARKET RESEARCH PVT. LTD.

Ready-to-Drink Beverages Market Size to Reach USD 1,227.81 Billion by 2032
Ready-to-Drink Beverages Market Size to Reach USD 1,227.81 Billion by 2032
Ready-to-Drink Beverages Market is poised for substantial growth over the forecast period, driven by changing consumer lifestyles, rising disposable income, expanding urbanization, and increasing demand for convenient beverage solutions. According to recent industry analysis, the global Ready-to-Drink Beverages Market was valued at USD 766.69 Billion in 2024 and is projected to grow at a compound annual growth rate (CAGR) of 6.22% from 2025 to 2032, reaching nearly USD 1,227.81 Billion
Second hand Product Market Set to Surpass USD 1451.34 Billion by 2032, Expanding at a Robust 13.6% CAGR
Second hand Product Market Set to Surpass USD 1451.34 Billion by 2032, Expanding …
Second hand Product Market was valued at USD 594.45 Billion in 2025 and is projected to grow at a robust CAGR of 13.6% from 2025 to 2032, reaching nearly USD 1451.34 Billion by 2032. The rapid expansion of resale ecosystems, increasing consumer preference for cost-effective purchasing, and rising sustainability awareness are significantly driving the growth of the Second hand Product Market globally. Market Overview The Second hand Product Market is undergoing a
Tungsten Market to Reach USD 10.99 Billion by 2032, Driven by Expanding Aerospace, Automotive, and Industrial Applications
Tungsten Market to Reach USD 10.99 Billion by 2032, Driven by Expanding Aerospac …
The Global Tungsten Market is poised for significant expansion over the coming years, with the market size valued at USD 6.41 Billion in 2025 and projected to grow at a CAGR of 8% from 2025 to 2032, reaching nearly USD 10.99 Billion by 2032. Rising industrial demand, technological advancements in material science, and increasing applications in high-performance sectors are collectively driving this steady growth trajectory. Tungsten, recognized for its exceptional hardness,
System-on-Chip (SoC) Market to Reach USD 391.61 Billion by 2032, Driven by 5G, AI, and IoT Expansion
System-on-Chip (SoC) Market to Reach USD 391.61 Billion by 2032, Driven by 5G, A …
The global System-on-Chip (SoC) Market is poised for significant growth over the forecast period, reflecting the rapid evolution of semiconductor technologies and increasing demand for high-performance, energy-efficient electronic devices. Valued at USD 228.06 Billion in 2025, the market is projected to grow at a CAGR of 8.03% from 2025 to 2032, reaching nearly USD 391.61 Billion by 2032. ♦ Request a Free Sample Copy or View Report Summary:https://www.maximizemarketresearch.com/request-sample/33954/ System-on-Chip (SoC) Market Overview A

All 5 Releases


More Releases for Alzheimer

Alzheimer Therapeutics Market Breakthrough Innovations and Increasing Treatment …
The Alzheimer Therapeutics Market is rapidly evolving as disease-modifying therapies, early-stage diagnostic tools, and biomarker-driven treatment approaches reshape global management of Alzheimer's disease (AD). As one of the most prevalent neurodegenerative conditions, Alzheimer's affects millions of older adults worldwide. With recent regulatory approvals of anti-amyloid monoclonal antibodies, enhanced imaging technology, and increased R&D investment, the market is experiencing unprecedented momentum. Download Full PDF Sample Copy of Market Report @ https://exactitudeconsultancy.com/request-sample/51928 Key Takeaways • Disease-modifying
Dementia - Alzheimer Disease Market: A Comprehensive Analysis 2030
Dementia and Alzheimer's disease represent significant challenges within the global healthcare sector. These neurological disorders, characterized by progressive cognitive decline, have seen increasing prevalence due to aging populations worldwide. This growing burden has spurred interest in the Dementia - Alzheimer's disease market, encompassing diagnostic tools, treatments, caregiving solutions, and related healthcare services. This article provides an overview of the market, its scope, current trends, and factors driving its expansion. Data Bridge
Alzheimer Disease Treatment Market | Allergan, Amgen, Daiichi Sankyo, Eisai
The global alzheimer disease treatment market report is a comprehensive report that provides a detailed analysis of the current status and future trends of the alzheimer disease treatment market worldwide. This report provides valuable information to industry stakeholders by offering an in-depth perspective on market dynamics, competitive landscape, growth opportunities, and key challenges faced by industry participants. From the perspective of market dynamics, this report explores the factors driving the growth
United States Alzheimer Drugs Market Insights Deep Analysis 2023-2031
Cognate Life Sciences introduces a report on "United States Alzheimer Drugs Market 2023" with Market Insights Reports, Introduces systematic details in terms of market valuation, market size, revenue estimation, and geographical spectrum of the business vertical. The study also talks about crucial pockets of the industry such as products or services offered, downstream fields, end using customers, historic data figures regarding revenue and sales, market context and more. It conjointly
Global Alzheimer Market, Global Alzheimer Industry, Covid-19 Impact Global Alzhe …
Alzheimer's is a progressive disease that leads to the death of brain cells, resulting in memory loss, behavioral issues, and disruption the thought processes. The Alzheimer disease is considered fatal. Age and heredity are the two main risk factors for developing Alzheimer's disease. Several other preventable risk factors have been associated to the development of this disease, including diet, environment, and overall general health. A combination of risk factors is
US Alzheimer Drug Pipeline Analysis
In US, the Alzheimer's disease is the 6th leading cause of death overall and among those aged 65 and above, it is the 5th leading cause of death. While the deaths from major diseases, like heart disease have decreased, the death due to Alzheimer's have increased by more than 60% between 2000 and 2012. The total number of patients having Alzheimer’s disease was 5.4 million in 2012. Out of this,